Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
15–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of CD for at least 3 months prior to baseline
Confirmed diagnosis of moderate to severe CD as assessed by SF, AP score, and SES-CD
Demonstrated intolerance, loss of response or inadequate response to conventional or to biologic therapy for CD
If female, subject must meet the contraception recommendations
You may not be if
Have a current diagnosis of ulcerative colitis, inflammatory bowel disease-unclassified (IBD-U) (formerly known as indeterminate colitis) or short bowel syndrome
Currently have or are suspected to have an abscess. Recent cutaneous and perianal abscesses are not exclusionary if drained, adequately treated and resolved at least 3 weeks prior to baseline or 8 weeks prior to baseline for intra-abdominal abscesses, provided that there is no anticipated need for any further surgery
Have a stoma, ileoanal pouch or ostomy
Have had a bowel resection within 6 months, or any kind of intra-abdominal or extra abdominal surgery within 3 months of baseline
Have ever received any monoclonal antibodies binding IL-23
Clareo Health | A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
